Please login to the form below

mantle cell lymphoma

This page shows the latest mantle cell lymphoma news and features for those working in and with pharma, biotech and healthcare.

FDA starts priority review of Kite’s CAR-T for mantle cell lymphoma

X19 in relapsed or refractory mantle cell lymphoma. ... Despite recent advances, patients with relapsed/refractory mantle cell lymphoma currently face a significant lack of effective treatment options once their disease no longer responds to currently

Latest news

EMA begins review of Kite’s CAR-T for mantle cell lymphoma

Kite is seeking approval for the CAR-T therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) – according to the company, if KTE-X19 is ... Relapse rates in mantle cell lymphoma remain overwhelmingly high and
BeiGene’s Brukinsa misses the mark in head-to-head Imbruvica trial

Failed to beat rival in rare white blood cell cancer. BeiGene’s BTK inhibitor Brukinsa was unable to beat rival Imbruvica from Johnson &Johnson/AbbVie in Waldenstrom’s macroglublinemia. . ... Brukinsa is BeiGene’s first drug to have been approved
Merck buys ArQule for $2.7bn in another cancer bolt-on deal

clinical activity in non-Hodgkin’s lymphoma (NHL) and an impressive three out of six responders in an aggressive form of NHL called Richter’s transformation. ... also in early-stage testing and had phase 1 results on show at ASH in CLL and mantle
China updates drug reimbursement list, agrees price cuts

Also included on the updated list is the PD-1 inhibitor Tyvyt (sintilimab) – jointly developed by Innovent Biologics and Eli Lilly – for the treatment of relapsed/refractory Hodgkin’s lymphoma. ... mantle cell lymphoma therapy Brukinsa.
AstraZeneca wins FDA approval for Calquence in chronic lymphoma

Calquence is already approved in mantle cell lymphoma (MCL), its first indication. ... AZ also has additional studies of Calquence in diseases such as multiple myeloma, Waldenström marcroglobulinaemia and diffuse large B-cell lymphoma, and claims that

More from news
Approximately 5 fully matching, plus 63 partially matching documents found.

Latest Intelligence

Encouraging signs in biomarker R&D

Similarly, high TMB is correlated with better response to immune checkpoint inhibitors, so is the presence of TIL or a T cell GEP. ... mantle cell lymphoma minimal as an example.
AstraZeneca: building a new ‘open innovation’ pharma company

AstraZeneca launched five significant new medicines in 2017: immunotherapy Iminzi, Calquence for mantle cell lymphoma, Qtern in type 2 diabetes, Bevespi Aerosphere in COPD and Fasenra for severe asthma.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

Virtual Engagement At Porterhouse: Reflections on the past few months: A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
July 2020: diversity and inclusion in clinical trials round-up: COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
Medical Device Clinical Trials 2020: In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...